Jacobs Levy Equity Management Inc. Purchases 304,420 Shares of Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Jacobs Levy Equity Management Inc. significantly increased its holdings in Aurinia Pharmaceuticals by 2,299.9%, owning 317,656 shares worth approximately $2.55 million after purchasing an additional 304,420 shares.
• Recent insider trading shows Director Kevin Tang purchased 1 million shares at $10.12 per share, bringing his total ownership to 11,029,500 shares, valued at around $111.6 million.
• Wall Street analysts have a consensus rating of "Buy" for Aurinia Pharmaceuticals, with price targets ranging from $9.00 to $17.00, indicating positive expectations for the company's growth.

Jacobs Levy Equity Management Inc. increased its position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 2,299.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 317,656 shares of the biotechnology company's stock after acquiring an additional 304,420 shares during the period. Jacobs Levy Equity Management Inc. owned about 0.23% of Aurinia Pharmaceuticals worth $2,554,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GF Fund Management CO. LTD. bought a new stake in Aurinia Pharmaceuticals during the 4th quarter worth $27,000. Tower Research Capital LLC TRC grew its position in Aurinia Pharmaceuticals by 368.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in Aurinia Pharmaceuticals during the 4th quarter worth $31,000. GAMMA Investing LLC grew its position in shares of Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after buying an additional 1,744 shares during the last quarter. Finally, MAI Capital Management bought a new stake in shares of Aurinia Pharmaceuticals in the 1st quarter valued at about $39,000. Institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Stock Down 0.3%

Shares of Aurinia Pharmaceuticals stock traded down $0.04 on Friday, hitting $12.74. The company had a trading volume of 1,369,249 shares, compared to its average volume of 1,528,409. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of 29.63 and a beta of 1.26. Aurinia Pharmaceuticals Inc has a 1 year low of $6.55 and a 1 year high of $12.87. The stock has a 50 day moving average of $10.76 and a 200-day moving average of $8.98. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.01). The company had revenue of $70.01 million during the quarter, compared to analysts' expectations of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on AUPH. Royal Bank Of Canada upped their price target on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research report on Friday, August 1st. HC Wainwright reissued a "buy" rating and issued a $17.00 price objective on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Aurinia Pharmaceuticals has an average rating of "Buy" and a consensus target price of $12.00.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang purchased 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 5th. The stock was bought at an average cost of $11.68 per share, with a total value of $2,336,000.00. Following the completion of the transaction, the director owned 11,329,500 shares of the company's stock, valued at $132,328,560. The trade was a 1.80% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders purchased 1,300,000 shares of company stock worth $13,590,000 over the last three months. Company insiders own 12.20% of the company's stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.